Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia
COPD in 2025: Year in Review
FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector
Nephrology in 2025: Year in Review
1.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
2.
TikTok creators perform 'roles' when sharing their hereditary cancer stories, shaping the health information they share
3.
Novel probes to label macrophages associated with cancer progression using a selective dye
4.
Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain
5.
A prostate cancer risk prediction algorithm could help target men at highest risk
1.
Targeting Oncology: Expanding Combinatorial Strategies by 2025
2.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
3.
Colon Cancer Staging: What You Need to Know
4.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
5.
Florinef: Understanding Its Uses and Side Effects
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge